Edition:
United States

Minerva Neurosciences Inc (NERV.OQ)

NERV.OQ on NASDAQ Stock Exchange Global Market

9.00USD
1:29pm EDT
Change (% chg)

$0.10 (+1.12%)
Prev Close
$8.90
Open
$8.90
Day's High
$9.10
Day's Low
$8.90
Volume
8,287
Avg. Vol
34,975
52-wk High
$10.15
52-wk Low
$4.90

Chart for

About

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $350.68
Shares Outstanding(Mil.): 38.75
Dividend: --
Yield (%): --

Financials

  NERV.OQ Industry Sector
P/E (TTM): -- 235.76 33.88
EPS (TTM): -1.10 -- --
ROI: -29.56 -5.45 13.21
ROE: -37.52 -6.94 15.18

BRIEF-Minerva Neurosciences Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

May 03 2018

BRIEF-Minerva Neurosciences Reports Q1 Loss Per Share $0.32

* MINERVA NEUROSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATES

May 03 2018

BRIEF-Minerva Neurosciences Screens First Patient In Phase 2B Trial Of Min 117 To Treat Major Depressive Disorder

* MINERVA NEUROSCIENCES SCREENS FIRST PATIENT IN PHASE 2B TRIAL OF MIN 117 TO TREAT MAJOR DEPRESSIVE DISORDER

Apr 09 2018

BRIEF-Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter And Year End Financial Results

* MINERVA NEUROSCIENCES REPORTS FISCAL 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS AND BUSINESS UPDATES

Mar 12 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

Feb 05 2018

BRIEF-Minerva Neurosciences Names Remy Luthringer As Executive Chairman

* MINERVA NEUROSCIENCES NAMES REMY LUTHRINGER AS EXECUTIVE CHAIRMAN AND WILLIAM DOYLE AS LEAD INDEPENDENT DIRECTOR

Feb 05 2018

Competitors

Earnings vs. Estimates